Absence of an apolipoprotein E ε4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer disease

Archives of Neurology

Volumn 55, Issue 11, 1998, Pages 1460-1466

  Van Dyck, Christopher H ^a   Gelernter, Joel ^a   MacAvoy, Martha G ^a   Avery, Robert A ^a   Criden, Marc ^a   Okereke, Olivia ^a   Varma, Pradeep ^a   Seibyl, John P ^a   Hoffer, Paul B ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; TECHNETIUM 99M;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN ASYMMETRY; BRAIN BLOOD FLOW; BRAIN METABOLISM; BRAIN SCINTISCANNING; CHROMOSOME ABERRATION; CLINICAL ARTICLE; FEMALE; HUMAN; MALE; NEUROPATHOLOGY; PARIETAL LOBE; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0031759503     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.11.1460     Document Type: Article

References (39)

1. Saunders AM, Strittmatter WJ, Schmechel DE, et al. Association of apolipoprotein E allele ε4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467-1472.
2. Schmechel DE, Saunders AM, Strittmatter WJ, et al. Increased amyloid β-peptide deposition as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci U S A. 1993;90:9649-9653.
3. Nagy NS, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience. 1995;69:757-761.
4. Gomez-Isla T, West HL, Rebeck GW, et al. Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease. Ann Neurol. 1996;39:62-70.
5. Norrman J, Brookes AJ, Yates C, St Clair D. Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease. Br J Psychiatry. 1995;167:533-536.
6. Poirier J, Delisle M-C, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer's disease. Proc Natl Acad Sci U S A. 1995;92:12260-12264.
7. Basun H, Grut M, Winblad B, Lannfelt L. Apolipoprotein ε4 allele and disease progression in patients with late-onset Alzheimer's disease. Neurosci Lett. 1995; 183:32-34.
8. Growdon JH, Locascio JJ, Corkin S, Gomez-Isla T, Hyman BT. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology. 1996;47:444-448.
9. Frisoni GB, Govoni S, Geroldi C, et al. Gene dose of the ε4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol. 1995;37:596-604.
10. Kurz A, Egensperger R, Haupt M, et al. Apolipoprotein E ε4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology. 1996;47:440-443.
11. Murphy GM, Taylor J, Kraemer HC, Yesavage J, Tinklenberg JR. No association between apolipoprotein E ε4 allele and rate of decline in Alzheimer's disease. Am J Psychiatry. 1997;154:603-608.
12. Stern Y, Brandt J, Albert M, et al. The absence of an apolipoprotein ε4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol. 1997; 41:615-620.
13. Lopez OL, Kamboh MI, Becker JT, Kaufer DI, DeKosky ST. The apolipoprotein E ε4 allele is not associated with psychiatric symptoms or extrapyramidal signs in probable Alzheimer's disease. Neurology. 1997;49:794-797.
14. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995;273:942-947.
15. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the ε4 allele for apolipoprotein E. N Engl J Med. 1996;334:752-758.
16. Lehtovirta M, Soininen H, Laakso MP, et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E ε4 allele. J Neurol Neurosurg Psychiatry. 1996;60:644-649.
17. Corder EH, Jelic V, Basun H, et al. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes. Arch Neurol. 1997;54:273-277.
18. Sharp PF, Smith FW, Gemmell HG, et al. Technetium-99m HM-PAO stereoisomers as potential agents for imaging regional cerebral blood flow: human volunteer studies. J Nucl Med. 1986;27:171-177.
19. Mirra SS, Heyman A, McKeel D, et al. The consortium to establish a registry for Alzheimer's disease (CERAD), II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41:479-486.
20. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-944.
21. Folstein MF, Fostein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
22. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-1364.
23. Lawlor BA, Ryan TM, Schmeidler J, Mohs RC, Davis KL. Clinical symptoms associated with age at onset in Alzheimer's disease. Am J Psychiatry. 1994;151: 1646-1649.
24. Breitner JCS, Folstein MF. Familial Alzheimer's disease: a prevalent disorder with specific clinical features. Psychol Med. 1984;14:63-80.
25. Silverman JM, Breitner JCS, Mohs RC, Davis KL. Reliability of the family history method in genetic studies of Alzheimer's disease and related dementias. Am J Psychiatry. 1986;143:1279-1282.
26. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res. 1990;31:545-548.
27. Tsai M-S, Tangalos EG, Petersen RC, et al. Apolipoprotein E: risk factor for Alzheimer disease. Am J Hum Genet. 1994;54:643-649.
28. van Dyck CH, Lin CH, Robinson R, et al. Comparison of technetium-99m-HMPAO and technetium-99m-ECD cerebral SPECT images in Alzheimer's disease. J Nucl Med. 1996;37:1749-1755.
29. van Dyck CH, Lin CH, Robinson R, et al. The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease. Psychopharmacology. 1997;132:217-226.
30. Genna S, Smith AP. The development of ASPECT, an annular single crystal brain camera for high efficiency SPECT. IEEE Trans Nucl Sci. 1988;NS-35:654-658.
31. Kirk R. Experimental Design: Procedures for the Behavioral Sciences. Pacific Grove, Calif: Brooks/Cole Publishing Co; 1982:126-127.
32. Chase TN, Foster NL, Fedio P, Brooks R, Mansi L, Di Chiro G. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography. Ann Neurol. 1984;15(suppl):S170-S174.
33. Small GW, Kuhl DE, Riege WH, et al. Cerebral glucose metabolic patterns in Alzheimer's disease: effect of gender and age at dementia onset. Arch Gen Psychiatry. 1989;46:527-532.
34. Arai H, Hanyu H, Abe S, et al. A comparison of cerebral hemodynamics in early and late onset Alzheimer's disease using SPECT [abstract]. J Nucl Med. 1994; 35:206P.
35. Mazziotta JC, Phelps ME. Positron emission tomography studies of the brain. In: Phelps M, Mazziotta J, Schelbert H, eds. Positron Emission Tomography and Autoradiography: Principles and Applications for the Brain and Heart. New York, NY: Raven Press; 1986:493-579.
36. McGeer PL, Kamo H, Harrop R, et al. Comparison of PET, MRI, and CT with pathology in a proven case of Alzheimer's disease. Neurology. 1986;36:1569-1574.
37. DeCarli C, Atack JR, Ball MJ, et al. Post-mortem regional neurofibrillary tangle densities but not senile plaque densities are related to regional cerebral metabolic rates for glucose during life in Alzheimer's disease patients. Neurodegeneration. 1992;1:113-121.
38. Wilcock GK, Esiri MM. Asymmetry of pathology in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1987;50:1384-1386.
39. Haxby JV, Grady CL, Koss E, et al. Longitudinal study of cerebral metabolic asymmetries and associated neuropsychological patterns in early dementia of the Alzheimer type. Arch Neurol. 1990;47:753-760.